Who Paid My Doc
Matthew Greenhawt
Pediatric Allergy/Immunology Aurora, CO Medical Doctor
NPI 1932226644 CMS profile 88014
13123 E 16Th Ave, Aurora, CO 80045
General payments
$308,121
Research payments
$3,757
Ownership & investment interest
$0
Research they led as principal investigator
$431,756
Through program year 2025, Matthew Greenhawt of Aurora, CO is reported in the CMS Open Payments database as having received $308,121 across 264 general payments and $3,757 in research payments paid to them. Separately, studies naming them as principal investigator received $431,756 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $219,881 | 176 | |
| 2024 | General | $39,344 | 37 | |
| 2023 | General | $6,349 | 15 | |
| 2023 | Research | $2,558 | 3 | |
| 2022 | General | $12,460 | 8 | |
| 2022 | Research | $196 | 1 | |
| 2021 | General | $14,690 | 8 | |
| 2021 | Research | $1,003 | 2 | |
| 2020 | General | $12,104 | 7 | |
| 2019 | General | $3,293 | 13 |
Beside peers
- Matthew Greenhawt
- Pediatric Allergy/Immunology median
- Middle half of Pediatric Allergy/Immunology
- National median
In program year 2025, general payments to Matthew Greenhawt were reported at $219,881. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.
Show as a table
| Year | Matthew Greenhawt | Pediatric Allergy/Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,293 | $325 | $92–$1,399 | $163 |
| 2020 | $12,104 | $144 | $66–$2,490 | $114 |
| 2021 | $14,690 | $357 | $95–$2,633 | $132 |
| 2022 | $12,460 | $385 | $125–$2,259 | $149 |
| 2023 | $6,349 | $470 | $121–$2,946 | $160 |
| 2024 | $39,344 | $317 | $125–$2,583 | $164 |
| 2025 | $219,881 | $361 | $125–$2,493 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
270 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Allergy/Immunology in Colorado
David Fleischer
Pediatric Allergy/Immunology · Aurora, CO
William Anderson
Pediatric Allergy/Immunology · Aurora, CO
Cullen Dutmer
Pediatric Allergy/Immunology · Aurora, CO
Andrew Liu
Pediatric Allergy/Immunology · Denver, CO
Matthew McCulloch
Pediatric Allergy/Immunology · Aurora, CO
Wen-Yuan Hsieh
Pediatric Allergy/Immunology · Aurora, CO
Related records
Pediatric Allergy/Immunology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Allergy/Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.